FDA Approves First-Ever Treatment for Chronic Hepatitis Delta Virus (HDV)
After years without any approved therapies in the United States, Gilead's Hepcludex has secured FDA approval for chronic hepatitis delta virus, the most severe form of viral hepatitis. The decision establishes a new standard of care for patients with compensated liver disease. It also creates a therapeutic market from zero.
Drug Profile
Mechanism of Action Hepcludex (bulevirtide) is a first-in-class viral entry inhibitor. It binds to and blocks the sodium taurocholate co-transporting polypeptide (NTCP), a bile acid transporter on the surface of hepatocytes. This receptor is the essential entry point for both Hepatitis B virus (HBV) and Hepatitis D virus (HDV) into liver cells. By preventing viral entry, bulevirtide disrupts the viral lifecycle, reduces the liver's exposure to new virions, and lowers liver inflammation.
Drug Class & Structure Bulevirtide is classified as a viral entry inhibitor. Structurally, it is a synthetic lipopeptide composed of 47 amino acids derived from the pre-S1 domain of the HBV large envelope protein. Its structure is engineered to mimic the viral binding site, allowing it to competitively inhibit the virus from docking with the NTCP receptor. This targeted, pre-replication mechanism is distinct from nucleos(t)ide analogues used in HBV that inhibit viral replication post-entry.
Clinical Data
The approval was supported by efficacy and safety data from mid- and late-stage clinical trials. The primary endpoint focused on a combined response, defined as a reduction in HDV RNA and normalization of alanine aminotransferase (ALT) levels, a key marker of liver inflammation.
| Endpoint | Result | Comparator | Trial | | :--- | :--- | :--- | :--- | | Combined Virological & Biochemical Response (Week 48) | 45% of patients achieved response | 2% of patients in delayed treatment arm | MYR-301 | | Alanine Aminotransferase (ALT) Normalization (Week 48) | 51% of patients | 6% of patients in delayed treatment arm | MYR-301 | | Undetectable HDV RNA (Week 48) | 12% of patients | 0% of patients in delayed treatment arm | MYR-301 |
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Regulatory Body | Status | |
| FDA (United States) | ✓ Approved (May 26, 2026) | |
| EMA (European Union) | ✓ Conditionally Approved (July 31, 2020) | |
| Health Canada | No submission entry detected in BrunoSan DB as of 2026-05-26. | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of 2026-05-26. |
STATUS The FDA's decision follows a conditional marketing authorization from the European Medicines Agency (EMA) nearly six years prior, highlighting a divergent regulatory timeline between the two major bodies for this asset.
Market Impact
Hepcludex enters a complete therapeutic vacuum in the United States. Prior to this approval, no specific treatments for HDV existed; management relied on supportive care and off-label interferon, which has limited efficacy and high toxicity. The competitive landscape is therefore nonexistent, positioning Hepcludex as the immediate and sole standard of care. The primary commercial challenge is not displacing a competitor but market creation. This involves driving diagnosis in the at-